New developments on thromboxane modulators.
Thromboxane A(2) (TXA(2)) is a labile product formed from arachidonic acid by cyclooxygenase. The pathogenesis of numerous cardiovascular, pulmonary, and thromboembolic diseases can be related to this metabolite. Therefore, TXA(2) modulators have been developed for 20 years. This review will highlight the evolution in the field of TXA(2) modulators.
Dogné
Jean-Michel
JM
Natural and Synthetic Drug Research Centre, Medicinal Chemistry, University of Liège, 1, av. de l'Hôpital, B-4000 Liège, Belgium. Jean-Michel.Dogne@ulg.ac.be
Hanson
Julien
J
de Leval
Xavier
X
Masereel
Bernard
B
Kolh
Philippe
P
Pirotte
Bernard
B
D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D017482:Receptors, Thromboxane / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000737:chemistry; D015398:Signal Transduction; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D017482:Receptors, Thromboxane; D013928:Thromboxane A2; D013930:Thromboxane-A Synthase